Biologic Treatment of Axial Spondyloarthritis

Filip Van Den Bosch; Philippe Carron; Philip Mease

doi:10.1016/B978-0-323-56800-5.00015-1

Biologic Treatment of Axial Spondyloarthritis

Filip Van Den Bosch
, Philippe Carron
, Philip Mease

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

4 Scopus citations

Abstract

This chapter reviews the evidence for current and emerging biologic therapy in axial spondyloarthritis and touches upon new treatment paradigms and the difference between late-stage radiographic and early non-radiographic disease.

Original language	English
Title of host publication	Axial Spondyloarthritis
Publisher	Elsevier
Pages	227-242
Number of pages	16
ISBN (Electronic)	9780323568005
DOIs	https://doi.org/10.1016/B978-0-323-56800-5.00015-1
State	Published - Jan 1 2019

Keywords

Ankylosing spondylitis
Axial spondyloarthritis
Biosimilars
IL12-23 inhibition
IL17 inhibition
IL23 inhibition
Management
TNF inhibition

Access to Document

10.1016/B978-0-323-56800-5.00015-1

Cite this

@inbook{e36e96ce45d3437a8d2484b22fd77ecd,

title = "Biologic Treatment of Axial Spondyloarthritis",

abstract = "This chapter reviews the evidence for current and emerging biologic therapy in axial spondyloarthritis and touches upon new treatment paradigms and the difference between late-stage radiographic and early non-radiographic disease.",

keywords = "Ankylosing spondylitis, Axial spondyloarthritis, Biosimilars, IL12-23 inhibition, IL17 inhibition, IL23 inhibition, Management, TNF inhibition",

author = "\{Van Den Bosch\}, Filip and Philippe Carron and Philip Mease",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-56800-5.00015-1",

language = "English",

pages = "227--242",

booktitle = "Axial Spondyloarthritis",

publisher = "Elsevier",

}

TY - CHAP

T1 - Biologic Treatment of Axial Spondyloarthritis

AU - Van Den Bosch, Filip

AU - Carron, Philippe

AU - Mease, Philip

PY - 2019/1/1

Y1 - 2019/1/1

N2 - This chapter reviews the evidence for current and emerging biologic therapy in axial spondyloarthritis and touches upon new treatment paradigms and the difference between late-stage radiographic and early non-radiographic disease.

AB - This chapter reviews the evidence for current and emerging biologic therapy in axial spondyloarthritis and touches upon new treatment paradigms and the difference between late-stage radiographic and early non-radiographic disease.

KW - Ankylosing spondylitis

KW - Axial spondyloarthritis

KW - Biosimilars

KW - IL12-23 inhibition

KW - IL17 inhibition

KW - IL23 inhibition

KW - Management

KW - TNF inhibition

UR - https://www.scopus.com/pages/publications/85099291341

U2 - 10.1016/B978-0-323-56800-5.00015-1

DO - 10.1016/B978-0-323-56800-5.00015-1

M3 - Chapter

AN - SCOPUS:85099291341

SP - 227

EP - 242

BT - Axial Spondyloarthritis

PB - Elsevier

ER -

Biologic Treatment of Axial Spondyloarthritis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this